Alvotech Faces Securities Claims After 34% Stock Drop Due to Misleading Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Stock Price Plunge: Alvotech's stock plummeted 34% on November 3, 2025, following allegations of issuing misleading business information, with an additional nearly 4% drop the next day, severely undermining investor confidence.
- Legal Action Initiated: The Rosen Law Firm is investigating potential securities claims on behalf of Alvotech shareholders, allowing investors to join a class action without upfront costs to seek compensation for their losses.
- FDA Response: On November 2, 2025, Alvotech announced that the FDA issued a complete response letter regarding its Biologics License Application, citing deficiencies found during an inspection of its Reykjavik facility, which must be resolved before approval, further unsettling the market.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling such cases, thereby enhancing investor trust in their representation.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.000
Low
8.00
Averages
10.67
High
14.00
Current: 5.000
Low
8.00
Averages
10.67
High
14.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
